| 
					Risks outweighed benefits of darbepoetin alfa in patients with type 2 diabetes ... - Endocrine Today			 | 
						
		 		 | 
		
				
		 		 | 
		
					
| 
Endocrine TodayDarbepoetin alfa did not decrease the risk for death, cardiovascular or renal events in patients with type 2 diabetes, chronic kidney disease and moderate ...  
 |